AbbVie (ABBV) announced the U.S. FDA has approved Rinvoq, 15 mg, once daily, for the treatment of adults with giant cell arteritis. This comes after the European Commission recently granted marketing authorization of Rinvoq for the treatment of GCA in adult patients.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie price target raised to $227 from $220 at Raymond James
- AbbVie price target raised to $204 from $200 at BofA
- AbbVie price target lowered to $205 from $230 at HSBC
- AbbVie: Strong Financial Performance and Growth Prospects Drive Positive Analyst Outlook
- AbbVie price target raised to $250 from $241 at Morgan Stanley